GSK
1,038 hedge funds and large institutions have $20.7B invested in GSK in 2026 Q1 according to their latest regulatory filings, with 142 funds opening new positions, 317 increasing their positions, 381 reducing their positions, and 84 closing their positions.
69% more first-time investments, than exits
New positions opened: 142 | Existing positions closed: 84
63% more call options, than puts
Call options by funds: $222M | Put options by funds: $137M
36% more funds holding in top 10
Funds holding in top 10: 11 → 15 (+4)
6% more capital invested
Capital invested by funds: $19.5B → $20.7B (+$1.15B)
4% more funds holding
Funds holding: 998 → 1,038 (+40)
1.01% less ownership
Funds ownership: 19.72% → 18.72% (-1%)
17% less repeat investments, than reductions
Existing positions increased: 317 | Existing positions reduced: 381
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$282M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$154M |
| 3 |
Goldman Sachs
New York
|
+$127M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$111M |
| 5 |
BlackRock
New York
|
+$94.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$534M |
| 2 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
-$292M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$227M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$145M |
| 5 |
Holocene Advisors
New York
|
-$141M |
GSK Hedge Fund Activity: Q1 2026 in Review
1,038 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2026, worth a combined $20.7B — up 5.9% from $19.5B a quarter earlier.
Buyers outnumbered sellers: 142 funds opened new GSK positions and 84 closed out — a net gain of 58 holders — while 317 added to existing stakes and 381 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $282M. The largest seller was Dodge & Cox, cutting an estimated $534M.
- 1,038 institutional investors held GSK (GSK) as of Q1 2026, up from 998 in Q4 2025.
- Funds reported $20.7B of GSK stock for Q1 2026, up 5.9% quarter-over-quarter.
- 142 funds opened new GSK positions in Q1 2026 and 84 closed out, a net change of +58 holders.
- The largest GSK buyer in Q1 2026 was Morgan Stanley, an estimated $282M added.
- The largest GSK seller in Q1 2026 was Dodge & Cox, an estimated $534M sold.
Based on aggregated 13F filings for Q1 2026.